

Month of Issue: December 2024

For more information contact firstnationspoct@flinders.edu.au



December 2024

Contents

1.	Nur	nber of current operational sites in each jurisdiction, Q4 2022 - Q3 2024	2
2.	Cur	nulative CT/NG/TV POC patient tests over time, Q1 2016 – Q3 2024	3
3.	Ove	erview of STI POC patient testing from Q4 2020 – Q3 2024	4
	a)	Number of STI POC patient tests per month by age group, Q4 2020 – Q3 2024	. 4
	b)	Number of STI POC patient tests per month by state/territory, Q4 2020 – Q3 2024	. 5
	c)	Proportion of STI POC patient tests per month by Aboriginal and Torres Strait Islander status, Q4 2020 – Q3 2024	. 6
	d)	Number of STI POC patient tests per month by gender, Q4 2020 – Q3 2024	. 7
4.	Ove	erview of STI POC patient test positivity for Q1 2023 to Q2 2024	. 8
	a)	Overall CT/NG/TV POC test positivity, Q1 2023 – Q3 2024	. 8
	b)	CT/NG/TV POC test positivity by Gender, Q1 2023 – Q3 2024	. 9
	c)	CT/NG/TV POC test positivity by Age, Q1 2023 – Q3 2024	10
	d)	CT/NG/TV POC test positivity by Remoteness, Q1 2023 – Q3 2024	11
	e)	Patient positivity, Q1 2023 – Q3 2024	12



December 2024

1. Number of current operational sites in each jurisdiction, Q4 2022 - Q3 2024





December 2024







December 2024

3. Overview of STI POC patient testing from Q4 2020 - Q3 2024





Legend 30 years or older

15 to 29 years



December 2024

b) Number of STI POC patient tests per month by state/territory, Q4 2020 – Q3 2024



December 2024

a

-8-





Note: The proportion of not reported has decreased over time following improved data capture across the network.



December 2024

1

RA

a.



d) Number of STI POC patient tests per month by gender, Q4 2020 – Q3 2024

Note: The proportion of not reported has decreased over time following improved data capture across the network



December 2024

4. Overview of STI POC patient test positivity for Q1 2023 to Q2 2024



a) Overall CT/NG/TV POC test positivity, Q1 2023 - Q3 2024

Note: Positivity is the number of positive patient tests divided by the number of patient tests. One CT/NG test is counted as two tests in the denominator. The dotted line represents the trend over time.



December 2024



b) CT/NG/TV POC test positivity by Gender, Q1 2023 – Q3 2024

Note: Positivity is the number of positive patient tests divided by the number of patient tests. One CT/NG test is counted as two tests in the denominator. The dotted line represents the trend over time for each respective population group.



December 2024



c) CT/NG/TV POC test positivity by Age, Q1 2023 - Q3 2024

Note: Positivity is the number of positive patient tests divided by the number of patient tests. One CT/NG test is counted as two tests in the denominator. The dotted line represents the trend over time for each respective population group.



December 2024



d) CT/NG/TV POC test positivity by Remoteness, Q1 2023 - Q3 2024

* Note: Positivity is the number of positive patient tests divided by the number of patient tests. One CT/NG test is counted as two tests in the denominator; variations in positivity over time by remoteness area may be due to increased enrolment in regional areas. The dotted line represents the trend over time for each respective population group.



December 2024

a

QQ

Co,

8

e) Patient positivity, Q1 2023 – Q3 2024



Patient positivity is the number of people who had any positive test result divided by the number people who had both a CT/NG and a TV test.